Opelkibart elmanitin

艾汀欧倍奇拜单抗

Report date: 2024/03/28 17:02:08

Base Information

Drug NameOpelkibart elmanitin

Drug Alias NameCD117-amanitin antibody drug conjugate (Magenta Therapeutics)Anti-CD117 amanitin antibody drug conjugate (Magenta Therapeutics)MGTA-117

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Amanitin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionRNA polymerase II inhibitorsStem cell growth factor receptor inhibitors

TargetsRNA polymerase IIStem cell growth factor receptor

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesHeidelberg Pharma AG

China Registration ClassN/A

Develop Information

Active CompaniesMagenta Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A